Carregant...

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

BACKGROUND: HER2 expression and amplification are observed in ~15% of tumour biopsies from patients with a sensitising EGFR mutation who develop EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumour responses. METHODS: A single arm phase II study was performe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: de Langen, Adrianus J., Jebbink, M., Hashemi, Sayed M. S., Kuiper, Justine L., de Bruin-Visser, J., Monkhorst, Kim, Thunnissen, Erik, Smit, Egbert F.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6162232/
https://ncbi.nlm.nih.gov/pubmed/30061586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0194-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!